FDA press release.Having to take one or more pills daily poses adherence problems for some people with HIV, so it’s important to have the option of a monthly injection, ViiV officials and scientists say.“FDA approval of Cabenuva represents a shift in the way HIV is treated, offering people living with HIV a completely new approach to care,” Lynn Baxter, who heads ViiV Healthcare’s North American operations, said in a company news release. “Cabenuva reduces the treatment dosing days from 365 days to 12 days per year.